{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:16:30Z","timestamp":1787958990577,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R21DA049539-01"],"award-info":[{"award-number":["1R21DA049539-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R21DA049539-01"],"award-info":[{"award-number":["1R21DA049539-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41386-024-01872-9","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:02:33Z","timestamp":1716555753000},"page":"1711-1718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-7145","authenticated-orcid":false,"given":"Cara C.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Papini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Roache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper A. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"1872_CR1","unstructured":"World Health Organization. Tobacco Fact Sheet. 2020. https:\/\/www.who.int\/docs\/default-source\/campaigns-and-initiatives\/world-no-tobacco-day-2020\/wntd-tobacco-fact-sheet.pdf"},{"key":"1872_CR2","unstructured":"Centers for Disease Control and Prevention. Smoking & Tobacco Use: Fast Facts and Fact Sheets. 2023. https:\/\/www.cdc.gov\/tobacco\/data_statistics\/fact_sheets\/fast_facts\/index.htm"},{"key":"1872_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.15585\/mmwr.mm7111a1","volume":"71","author":"ME Cornelius","year":"2022","unstructured":"Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM. Tobacco product use among adults\u2014United States, 2020. MMWR Morb Mortal Wkly Rep. 2022;71:397\u2013405.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1872_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.amepre.2014.10.012","volume":"48","author":"X Xu","year":"2015","unstructured":"Xu X, Bishop EE, Kennedy SM, Simpson SA, Pechacek TF. Annual healthcare spending attributable to cigarette smoking: an update. Am J Prev Med. 2015;48:326\u201333.","journal-title":"Am J Prev Med"},{"key":"1872_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amepre.2022.04.032","volume":"63","author":"SS Shrestha","year":"2022","unstructured":"Shrestha SS, Ghimire R, Wang X, Trivers KF, Homa DM, Armour BS. Cost of cigarette smoking\u2012attributable productivity losses, U.S., 2018. Am J Prev Med. 2022;63:478\u201385.","journal-title":"Am J Prev Med"},{"key":"1872_CR6","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2105\/AJPH.2012.300805","volume":"102","author":"W Max","year":"2012","unstructured":"Max W, Sung H-Y, Shi Y. Deaths from secondhand smoke exposure in the United States: economic implications. Am J Public Health. 2012;102:2173\u201380.","journal-title":"Am J Public Health"},{"key":"1872_CR7","unstructured":"United States Public Health Service, Office of the Surgeon General, National Center for Chronic Disease Prevention and Health Promotion (U.S.), Office on Smoking and Health. Smoking Cessation: A Report of the Surgeon General. Washington, DC: U.S. Department of Health and Human Services; 2020."},{"key":"1872_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02177-5","volume":"12","author":"Y Vandaele","year":"2022","unstructured":"Vandaele Y, Daeppen J-B. From concepts to treatment: a dialog between a preclinical researcher and a clinician in addiction medicine. Transl Psychiatry. 2022;12:401.","journal-title":"Transl Psychiatry"},{"key":"1872_CR9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41380-023-01942-2","volume":"28","author":"X Liu","year":"2023","unstructured":"Liu X, Yuan K, Lu T, Lin X, Zheng W, Xue Y, et al. Preventing incubation of drug craving to treat drug relapse: from bench to bedside. Mol Psychiatry. 2023;28:1415\u201329.","journal-title":"Mol Psychiatry"},{"key":"1872_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jsat.2008.06.005","volume":"36","author":"SG Ferguson","year":"2009","unstructured":"Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat. 2009;36:235\u201343.","journal-title":"J Subst Abuse Treat"},{"key":"1872_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrn1298","volume":"5","author":"SR Laviolette","year":"2004","unstructured":"Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci. 2004;5:55\u201365.","journal-title":"Nat Rev Neurosci"},{"key":"1872_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/sj.mp.4001507","volume":"9","author":"ND Volkow","year":"2004","unstructured":"Volkow ND, Fowler JS, Wang G-J, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9:557\u201369.","journal-title":"Mol Psychiatry"},{"key":"1872_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/mp.2009.16","volume":"14","author":"N Hiroi","year":"2009","unstructured":"Hiroi N, Scott D. Constitutional mechanisms of vulnerability and resilience to nicotine dependence. Mol Psychiatry. 2009;14:653\u201367.","journal-title":"Mol Psychiatry"},{"key":"1872_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.neuro.29.051605.113009","volume":"29","author":"SE Hyman","year":"2006","unstructured":"Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci. 2006;29:565\u201398.","journal-title":"Annu Rev Neurosci"},{"key":"1872_CR15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760\u201373.","journal-title":"Lancet Psychiatry"},{"key":"1872_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/1064-1297.16.3.207","volume":"16","author":"CA Conklin","year":"2008","unstructured":"Conklin CA, Robin N, Perkins KA, Salkeld RP, McClernon FJ. Proximal versus distal cues to smoke: the effects of environments on smokers\u2019 cue-reactivity. Exp Clin Psychopharmacol. 2008;16:207\u201314.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1872_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1037\/1064-1297.7.1.56","volume":"7","author":"AB Lazev","year":"1999","unstructured":"Lazev AB, Herzog TA, Brandon TH. Classical conditions of environmental cues to cigarette smoking. Exp Clin Psychopharmacol. 1999;7:56\u201363.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1872_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14622200701365178","volume":"9","author":"KS Bagot","year":"2007","unstructured":"Bagot KS, Heishman SJ, Moolchan ET. Tobacco craving predicts lapse to smoking among adolescent smokers in cessation treatment. Nicotine Tob Res. 2007;9:647\u201352.","journal-title":"Nicotine Tob Res"},{"key":"1872_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.biopsych.2009.12.034","volume":"67","author":"AC Janes","year":"2010","unstructured":"Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry. 2010;67:722\u20139.","journal-title":"Biol Psychiatry"},{"key":"1872_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1360-0443.1999.9433273.x","volume":"94","author":"BL Carter","year":"1999","unstructured":"Carter BL, Tiffany ST. Meta-analysis of cue-reactivity in addiction research. Addiction. 1999;94:327\u201340.","journal-title":"Addiction"},{"key":"1872_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/adb.12549","volume":"23","author":"MM Owens","year":"2018","unstructured":"Owens MM, MacKillop J, Gray JC, Beach SRH, Stein MD, Niaura RS, et al. Neural correlates of tobacco cue reactivity predict duration to lapse and continuous abstinence in smoking cessation treatment. Addict Biol. 2018;23:1189\u201399.","journal-title":"Addict Biol"},{"key":"1872_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamapsychiatry.2022.1240","volume":"79","author":"N Vafaie","year":"2022","unstructured":"Vafaie N, Kober H. Association of drug cues and craving with drug use and relapse: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79:641\u201350.","journal-title":"JAMA Psychiatry"},{"key":"1872_CR23","doi-asserted-by":"publisher","first-page":"106013","DOI":"10.1016\/j.cct.2020.106013","volume":"94","author":"S Papini","year":"2020","unstructured":"Papini S, Young CC, Gebhardt CS, Perrone A, Morikawa H, Otto MW, et al. Isradipine enhancement of virtual reality cue exposure for smoking cessation: rationale and study protocol for a double-blind randomized controlled trial. Contemp Clin Trials. 2020;94:106013.","journal-title":"Contemp Clin Trials"},{"key":"1872_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1124\/pharmrev.120.000245","volume":"73","author":"HJ Little","year":"2021","unstructured":"Little HJ. L-type calcium channel blockers: a potential novel therapeutic approach to drug dependence. Pharmacol Rev. 2021;73:127\u201354.","journal-title":"Pharmacol Rev"},{"key":"1872_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0091-3057(97)00334-1","volume":"58","author":"PM Gonzales","year":"1997","unstructured":"Gonzales PM, Boswell KJ, Hubbell CL, Reid LD. Isradipine blocks cocaine\u2019s ability to facilitate pressing for intracranial stimulation. Pharmacol Biochem Behav. 1997;58:1117\u201322.","journal-title":"Pharmacol Biochem Behav"},{"key":"1872_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF02245212","volume":"113","author":"MC Martellotta","year":"1994","unstructured":"Martellotta MC, Kuzmin A, Muglia P, Gessa GL, Fratta W. Effects of the calcium antagonist isradipine on cocaine intravenous self-administration in rats. Psychopharmacology. 1994;113:378\u201380.","journal-title":"Psychopharmacology"},{"key":"1872_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1749-6632.1998.tb08235.x","volume":"844","author":"K Mills","year":"1998","unstructured":"Mills K, Ansah TA, Ali SF, Shockley DC. Calcium Channel Antagonist Isradipine Attenuates Cocaine-Induced Motor Activity in Rats: Correlation with Brain Monoamine Levelsa. Ann N Y Acad Sci. 1998;844:201\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"1872_CR28","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1038\/s41386-018-0080-2","volume":"43","author":"NA Addy","year":"2018","unstructured":"Addy NA, Nunes EJ, Hughley SM, Small KM, Baracz SJ, Haight JL, et al. The L-type calcium channel blocker, isradipine, attenuates cue-induced cocaine-seeking by enhancing dopaminergic activity in the ventral tegmental area to nucleus accumbens pathway. Neuropsychopharmacology. 2018;43:2361\u201372.","journal-title":"Neuropsychopharmacology"},{"key":"1872_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0893-133X(94)00080-J","volume":"12","author":"O Pucilowski","year":"1995","unstructured":"Pucilowski O, P\u0142a\u017anik A, Overstreet DH. Isradipine suppresses amphetamine-induced conditioned place preference and locomotor stimulation in the rat. Neuropsychopharmacology. 1995;12:239\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"1872_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/mp.2015.84","volume":"21","author":"M Degoulet","year":"2016","unstructured":"Degoulet M, Stelly CE, Ahn K-C, Morikawa H. L-type Ca2+ channel blockade with antihypertensive medication disrupts VTA synaptic plasticity and drug-associated contextual memory. Mol Psychiatry. 2016;21:394\u2013402.","journal-title":"Mol Psychiatry"},{"key":"1872_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1037\/pha0000633","volume":"31","author":"S Natal","year":"2023","unstructured":"Natal S, Young CC, Kaur K, Gebhardt ES, Perrone A, Morikawa H, et al. Applications of isradipine in human addiction studies: a systematic literature review. Exp Clin Psychopharmacol. 2023;31:507\u201322.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1872_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1360-0443.2002.00014.x","volume":"97","author":"CA Conklin","year":"2002","unstructured":"Conklin CA, Tiffany ST. Applying extinction research and theory to cue exposure addiction treatments. Addiction. 2002;97:155\u201367.","journal-title":"Addiction"},{"key":"1872_CR33","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1017\/S0033291722002070","volume":"53","author":"E Malbos","year":"2023","unstructured":"Malbos E, Borwell B, Einig-Iscain M, Korchia T, Cantalupi R, Boyer L, et al. Virtual reality cue exposure therapy for tobacco relapse prevention: a comparative study with standard intervention. Psychol Med. 2023;53:5070\u201380.","journal-title":"Psychol Med"},{"key":"1872_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2019.01409","volume":"13","author":"T Segawa","year":"2020","unstructured":"Segawa T, Baudry T, Bourla A, Blanc JV, Peretti CS, Mouchabac S, et al. Virtual reality (VR) in assessment and treatment of addictive disorders: A systematic review. Front Neurosci. 2020;13:1\u201314.","journal-title":"Front Neurosci"},{"key":"1872_CR35","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22\u201333.","journal-title":"J Clin Psychiatry"},{"key":"1872_CR36","unstructured":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013."},{"key":"1872_CR37","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266\u201377.","journal-title":"Am J Psychiatry"},{"key":"1872_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neubiorev.2020.04.018","volume":"115","author":"AA Conti","year":"2020","unstructured":"Conti AA, Tolomeo S, Steele JD, Baldacchino AM. Severity of negative mood and anxiety symptoms occurring during acute abstinence from tobacco: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;115:48\u201363.","journal-title":"Neurosci Biobehav Rev"},{"key":"1872_CR39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ntr\/nts205","volume":"15","author":"KA Perkins","year":"2013","unstructured":"Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. Nicotine Tob Res. 2013;15:978\u201382.","journal-title":"Nicotine Tob Res"},{"key":"1872_CR40","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0893-133X(99)00116-5","volume":"22","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Ait-Daoud N, Wells LT. Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans. Neuropsychopharmacology. 2000;22:504\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"1872_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/01.jcp.0000115662.45074.c3","volume":"24","author":"BA Johnson","year":"2004","unstructured":"Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Mauldin JB. Effects of isradipine on cocaine-induced subjective mood. J Clin Psychopharmacol. 2004;24:180\u201391.","journal-title":"J Clin Psychopharmacol"},{"key":"1872_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s002130051007","volume":"144","author":"BA Johnson","year":"1999","unstructured":"Johnson BA, Roache JD, Bordnick PS, Ait-Daoud N. Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine\u2019s positive subjective effects: a preliminary study. Psychopharmacology. 1999;144:295\u2013300.","journal-title":"Psychopharmacology"},{"key":"1872_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1017\/S1461145705005511","volume":"8","author":"BA Johnson","year":"2005","unstructured":"Johnson BA, Roache JD, Ait-Daoud N, Wallace CL, Wells LT, Wang Y, et al. Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals. Int J Neuropsychopharmacol. 2005;8:549\u201356.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1872_CR44","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.amjhyper.2005.01.020","volume":"18","author":"BA Johnson","year":"2005","unstructured":"Johnson BA, Wells LT, Roache JD, Wallace C, Ait-Daoud N, Wang Y. Isradipine decreases the hemodynamic response of cocaine and methamphetamine: results from two human laboratory studies. Am J Hypertens. 2005;18:813\u201322.","journal-title":"Am J Hypertens"},{"key":"1872_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1037\/1064-1297.13.4.319","volume":"13","author":"JD Roache","year":"2005","unstructured":"Roache JD, Johnson BA, Ait-Daoud N, Mauldin JB, Thornton JE, Wells LT, et al. Effects of repeated-dose isradipine on the abuse liability of cocaine. Exp Clin Psychopharmacol. 2005;13:319\u201326.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1872_CR46","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00213-012-2750-9","volume":"226","author":"MM Torregrossa","year":"2013","unstructured":"Torregrossa MM, Taylor JR. Learning to forget: manipulating extinction and reconsolidation processes to treat addiction. Psychopharmacology. 2013;226:659\u201372.","journal-title":"Psychopharmacology"},{"key":"1872_CR47","doi-asserted-by":"publisher","first-page":"1167283","DOI":"10.3389\/fpsyt.2023.1167283","volume":"14","author":"M Luo","year":"2023","unstructured":"Luo M, Gan Q, Fu Y, Chen Z. Cue-reactivity targeted smoking cessation intervention in individuals with tobacco use disorder: a scoping review. Front Psychiatry. 2023;14:1167283.","journal-title":"Front Psychiatry"},{"key":"1872_CR48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ntr\/ntv216","volume":"18","author":"I Pericot-Valverde","year":"2016","unstructured":"Pericot-Valverde I, Germeroth LJ, Tiffany ST. The use of virtual reality in the production of cue-specific craving for cigarettes: a meta-analysis. Nicotine Tob Res. 2016;18:538\u201346.","journal-title":"Nicotine Tob Res"},{"key":"1872_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/ntr\/ntaa147","volume":"23","author":"JM Betts","year":"2021","unstructured":"Betts JM, Dowd AN, Forney M, Hetelekides E, Tiffany ST. A meta-analysis of cue reactivity in tobacco cigarette smokers. Nicotine Tob Res. 2021;23:249\u201358.","journal-title":"Nicotine Tob Res"},{"key":"1872_CR50","unstructured":"R Core Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013."},{"key":"1872_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367.","journal-title":"J Stat Softw"},{"key":"1872_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58168-7","volume":"14","author":"B Schr\u00f6der","year":"2024","unstructured":"Schr\u00f6der B, Kroczek A, Kroczek LOH. Cigarette craving in virtual reality cue exposure in abstainers and relapsed smokers. Sci Rep. 2024;14:7538.","journal-title":"Sci Rep"},{"key":"1872_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1037\/0022-006X.74.2.276","volume":"74","author":"S Shiffman","year":"2006","unstructured":"Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74:276\u201385.","journal-title":"J Consult Clin Psychol"},{"key":"1872_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1037\/0022-006X.68.2.233","volume":"68","author":"ST Tiffany","year":"2000","unstructured":"Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol. 2000;68:233\u201340.","journal-title":"J Consult Clin Psychol"},{"key":"1872_CR55","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1037\/0022-006X.72.6.1136","volume":"72","author":"AJ Waters","year":"2004","unstructured":"Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol. 2004;72:1136\u201343.","journal-title":"J Consult Clin Psychol"},{"key":"1872_CR56","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/s41380-019-0513-2","volume":"25","author":"CC Bavley","year":"2020","unstructured":"Bavley CC, Fetcho RN, Burgdorf CE, Walsh AP, Fischer DK, Hall BS, et al. Cocaine- and stress-primed reinstatement of drug-associated memories elicit differential behavioral and frontostriatal circuit activity patterns via recruitment of L-type Ca2+ channels. Mol Psychiatry. 2020;25:2373\u201391.","journal-title":"Mol Psychiatry"},{"key":"1872_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejphar.2006.03.017","volume":"537","author":"G Biala","year":"2006","unstructured":"Biala G, Budzynska B. Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur J Pharmacol. 2006;537:85\u201393.","journal-title":"Eur J Pharmacol"},{"key":"1872_CR58","doi-asserted-by":"publisher","first-page":"109290","DOI":"10.1016\/j.neuropharm.2022.109290","volume":"221","author":"H Morikawa","year":"2022","unstructured":"Morikawa H, Young CC, Smits J. Usage of L-type calcium channel blockers to suppress drug reward, memory and addiction: past, present, and future. Neuropharm. 2022;221:109290.","journal-title":"Neuropharm"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01872-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:04:33Z","timestamp":1726218273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01872-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1872"],"URL":"https:\/\/doi.org\/10.1038\/s41386-024-01872-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.31219\/osf.io\/bfe9k_v1","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MO: No conflicts in relation to the topic of this manuscript, but he is compensated for his role as an advisor for Big Health and also receives grant funding from Big Health. JS reports receiving grants from the NIH and DOD and personal fees from Big Health, Elsevier, American Psychological Association, Oxford University Press, and Springer. He also has equity ownership in Earkick, Inc. Earkick does not develop products that are related to the current study. HM receives current funding from NIH\/NIDA [R01DA054274].\u00a0The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}